Oncology

Australia's TGA approves Claritas iPET™, an AI tool that promises faster, lower-dose PET scans, boosting hospital efficiency and patient safety.

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

As Galapagos pivots its strategy, it brings in a new HR chief to build the high-performing culture crucial for its next chapter of innovation.

Taiwanese biotech GNTbm's oral drug GNTbm-38, which turns 'cold' tumors 'hot', will begin Phase 1 trials for advanced and refractory cancers.

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

New study shows an AI platform matches expert radiologists in tumor measurement, promising a new era of precision and consistency in breast cancer surgery.

A NY startup is using quantum computing and AI to fight aging at its source. Can Allosteric Bioscience's high-tech approach unlock a longer, healthier life?

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

With four new partners and a zero-markup model, Harrison.ai's Open Platform aims to democratize access to powerful medical AI tools for providers globally.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

MAIA Biotechnology secured a crucial $30M to advance its promising lung cancer drug, but the move sent its stock plunging amid investor fears of dilution.

With a pivotal trial for pancreatic cancer looming, Immuneering will detail its novel 'Deep Cyclic Inhibitor' platform and strategy to investors.

Peli BioThermal and Polar Group partner to upgrade Brazil's pharma logistics, tackling a booming market and ensuring safer delivery of advanced medicines.

A strategic deal between TAG1 and Dana-Farber seeks to solve a critical isotope shortage, accelerating the development of potent, targeted cancer treatments.

A new study aims to confirm a novel immunotherapy's dramatic results in colorectal cancer, offering hope for patients with limited treatment options.

Halia Therapeutics is betting on a novel target to fight chronic inflammation. At a key summit, it will pitch its unique approach for cancer, obesity, and Alzheimer's.

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.